top of page

35+ YEARS IN MEDICAL DEVICE | PHARMACEUTICAL | BIOTECHNOLOGY | DIAGNOSTICS

Insights and News Curated for Life Science Experts by Life Science Experts....

Go back to...

Executive Spotlights

Lesson’s Learned from Building out the Commercial Organization

SK Life Science breaks through Covid barriers to bring epilepsy drug to market

Lutronic’s Focus on Change during the Pandemic

From Big Pharma to Startup: What are the Challenges?

The View from Olympus: How This MedTech Leader Approached the Pandemic

DENTALEZ COO Heather Trombley on Reinvigorating the Company

Seqirus Exec on Vaccine Differentiation

Zimmer Biomet VP on Covering the Territory

How Teleflex Grew its Market Value 4x in 6 Years

Admedus COO David St. Denis on Courage, Commitment and Conversation

Search

Ollin Biosciences Raises $330M in Oversubscribed Series B to Advance Late-Stage Eye Disease Programs

Jul 1
1 min read

San Diego, CA, June 24, 2026 (Business Wire) -- Ollin Biosciences has secured $330 million in an oversubscribed Series B financing round to support global Phase 3 development of OLN324. The funding will be used to advance studies in diabetic macular edema (DME) and wet age-related macular degeneration (AMD), with trials scheduled to begin in the second half of 2026. The financing strengthens the company’s resources as it moves its lead ophthalmology candidate into late-stage clinical development.

Read full article here.

Recent Posts

EQT to Acquire TachoSil Biosurgery Business from Corza Medical

Stockholm, Sweden, July 7, 2026 (EQT) -- EQT has agreed to acquire the TachoSil biosurgery business from Corza Medical. The transaction will establish TachoSil as an independent company focused on a

ARS Pharmaceuticals Appoints Richard Lowenthal as CEO Following Leadership Transition

San Diego, CA, July 7, 2026 (Globe Newswire) -- ARS Pharmaceuticals has announced a CEO succession plan, with Richard Lowenthal assuming the role of chief executive officer. The leadership transitio

Novartis to Acquire Myricx Bio in Up to $2.9B Deal to Expand ADC Cancer Pipeline

Basel, Switzerland, July 6, 2026 (Novartis) -- Novartis has agreed to acquire Myricx Bio in a deal valued at up to $2.9 billion. The acquisition adds Myricx Bio’s next-generation antibody-drug conju

Life Science Headlines

EQT to Acquire TachoSil Biosurgery Business from Corza Medical

ARS Pharmaceuticals Appoints Richard Lowenthal as CEO Following Leadership Transition

Novartis to Acquire Myricx Bio in Up to $2.9B Deal to Expand ADC Cancer Pipeline

ARK Surgical Appoints Joseph B. Labruzzo as President and CEO of U.S. Operations

Vertex to Acquire Crinetics in $10B Deal to Expand Endocrinology Portfolio

Ollin Biosciences Raises $330M in Oversubscribed Series B to Advance Late-Stage Eye Disease Programs

BD Appoints Brian Thompson as President of Pharmacy Automation Business

AbbVie to Acquire Apogee Therapeutics in $1.8B Deal to Expand Immunology Portfolio

Pixee Medical Appoints Kristoff Goson as CEO to Accelerate U.S. Market Expansion

Merck KGaA to Acquire Bio-Techne in $17B Deal to Expand Life Sciences Leadership

bottom of page